NYXH Fundamental Analysis - NYXOAH SA

Fundamental Rating

NYXH gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 186 industry peers in the Health Care Equipment & Supplies industry. NYXH may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, NYXH is valued expensive at the moment.

Quickly go to:

1. Profitability

1.1 Basic Checks

NYXH had negative earnings in the past year.

NYXH had a negative operating cash flow in the past year.

In the past 5 years NYXH always reported negative net income.

NYXH had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

NYXH has a worse Return On Assets (-89.36%) than 77.96% of its industry peers.

The Return On Equity of NYXH (-164.71%) is worse than 69.89% of its industry peers.

		Industry Rank	Sector Rank
ROA	-89.36%
ROE	-164.71%
ROIC	N/A

ROA(3y)-31.13%

ROA(5y)-24.06%

ROE(3y)-40.68%

ROE(5y)-30.64%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

NYXH's Gross Margin of 64.33% is fine compared to the rest of the industry. NYXH outperforms 66.13% of its industry peers.

In the last couple of years the Gross Margin of NYXH has remained more or less at the same level.

The Profit Margin and Operating Margin are not available for NYXH so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	64.33%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y0.63%

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

NYXH does not have a ROIC to compare to the WACC, probably because it is not profitable.

NYXH has more shares outstanding than it did 1 year ago.

Compared to 5 years ago, NYXH has more shares outstanding

NYXH has a worse debt/assets ratio than last year.

2.2 Solvency

Based on the Altman-Z score of -4.30, we must say that NYXH is in the distress zone and has some risk of bankruptcy.

The Altman-Z score of NYXH (-4.30) is worse than 68.82% of its industry peers.

A Debt/Equity ratio of 0.39 indicates that NYXH is not too dependend on debt financing.

The Debt to Equity ratio of NYXH (0.39) is comparable to the rest of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0.39
Debt/FCF	N/A
Altman-Z	-4.3

ROIC/WACCN/A

WACC7.37%

2.3 Liquidity

A Current Ratio of 1.67 indicates that NYXH should not have too much problems paying its short term obligations.

The Current ratio of NYXH (1.67) is worse than 69.89% of its industry peers.

NYXH has a Quick Ratio of 1.38. This is a normal value and indicates that NYXH is financially healthy and should not expect problems in meeting its short term obligations.

NYXH has a worse Quick ratio (1.38) than 61.29% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	1.67
Quick Ratio	1.38

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The earnings per share for NYXH have decreased strongly by -30.42% in the last year.

The Revenue has grown by 10.92% in the past year. This is quite good.

The Revenue has been growing by 74.42% on average over the past years. This is a very strong growth!

EPS 1Y (TTM)-30.42%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-27.02%

Revenue 1Y (TTM)10.92%

Revenue growth 3Y74.42%

Revenue growth 5YN/A

Sales Q2Q%55.77%

3.2 Future

Based on estimates for the next years, NYXH will show a small growth in Earnings Per Share. The EPS will grow by 2.64% on average per year.

NYXH is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 117.81% yearly.

EPS Next Y-22.33%

EPS Next 2Y-8.48%

EPS Next 3Y2.64%

EPS Next 5YN/A

Revenue Next Year48.25%

Revenue Next 2Y136.46%

Revenue Next 3Y138.58%

Revenue Next 5Y117.81%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

NYXH reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year NYXH is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-8.48%

EPS Next 3Y2.64%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for NYXH!.

		Industry Rank	Sector Rank
Dividend Yield	0%

More info and screens

Find the best dividend stocks

Show peers with best dividend

NYXOAH SA

NASDAQ:NYXH (12/31/2025, 4:30:02 PM)

After market: 4.7 +0.1 (+2.17%)

4.6

-0.05 (-1.08%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupHealth Care Equipment & Services

GICS IndustryHealth Care Equipment & Supplies

Earnings (Last)11-13 2025-11-13/amc

Earnings (Next)03-11 2026-03-11/amc

Inst Owners17.62%

Inst Owner Change-23.67%

Ins Owners19.2%

Ins Owner ChangeN/A

Market Cap197.94M

Revenue(TTM)5.64M

Net Income(TTM)-84.00M

Analysts81.43

Price Target11.22 (143.91%)

Short Float %0.96%

Short Ratio6.6

Dividend

		Industry Rank	Sector Rank
Dividend Yield	0%

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)1

Avg EPS beat(2)0.07%

Min EPS beat(2)-5.02%

Max EPS beat(2)5.16%

EPS beat(4)2

Avg EPS beat(4)-4.98%

Min EPS beat(4)-22.16%

Max EPS beat(4)5.16%

EPS beat(8)5

Avg EPS beat(8)-2.41%

EPS beat(12)6

Avg EPS beat(12)-9.44%

EPS beat(16)9

Avg EPS beat(16)-3.71%

Revenue beat(2)0

Avg Revenue beat(2)-1.35%

Min Revenue beat(2)-1.4%

Max Revenue beat(2)-1.3%

Revenue beat(4)0

Avg Revenue beat(4)-19.45%

Min Revenue beat(4)-38.43%

Max Revenue beat(4)-1.3%

Revenue beat(8)1

Avg Revenue beat(8)-18.47%

Revenue beat(12)1

Avg Revenue beat(12)-25.3%

Revenue beat(16)1

Avg Revenue beat(16)-32.33%

PT rev (1m)-23.35%

PT rev (3m)-25.98%

EPS NQ rev (1m)2.52%

EPS NQ rev (3m)-2.46%

EPS NY rev (1m)2.01%

EPS NY rev (3m)-3.58%

Revenue NQ rev (1m)-6.97%

Revenue NQ rev (3m)-11.2%

Revenue NY rev (1m)-5.58%

Revenue NY rev (3m)-19.68%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	29.87
P/FCF	N/A
P/OCF	N/A
P/B	3.3
P/tB	168.36
EV/EBITDA	N/A

EPS(TTM)-2.64

EYN/A

EPS(NY)-2.49

Fwd EYN/A

FCF(TTM)-1.89

FCFYN/A

OCF(TTM)-1.86

OCFYN/A

SpS0.15

BVpS1.39

TBVpS0.03

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-89.36%
ROE	-164.71%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	64.33%
FCFM	N/A

ROA(3y)-31.13%

ROA(5y)-24.06%

ROE(3y)-40.68%

ROE(5y)-30.64%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y0.63%

GM growth 5YN/A

F-Score3

Asset Turnover0.06

Health

		Industry Rank	Sector Rank
Debt/Equity	0.39
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	47.99%
Cap/Sales	21.82%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	1.67
Quick Ratio	1.38
Altman-Z	-4.3

F-Score3

WACC7.37%

ROIC/WACCN/A

Cap/Depr(3y)64.93%

Cap/Depr(5y)74.76%

Cap/Sales(3y)37.37%

Cap/Sales(5y)219.8%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-30.42%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-27.02%

EPS Next Y-22.33%

EPS Next 2Y-8.48%

EPS Next 3Y2.64%

EPS Next 5YN/A

Revenue 1Y (TTM)10.92%

Revenue growth 3Y74.42%

Revenue growth 5YN/A

Sales Q2Q%55.77%

Revenue Next Year48.25%

Revenue Next 2Y136.46%

Revenue Next 3Y138.58%

Revenue Next 5Y117.81%

EBIT growth 1Y-59.61%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year-47.24%

EBIT Next 3Y-14.81%

EBIT Next 5Y11.04%

FCF growth 1Y-50.06%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-56.44%

OCF growth 3YN/A

OCF growth 5YN/A

NYXOAH SA / NYXH FAQ

What is the fundamental rating for NYXH stock?

ChartMill assigns a fundamental rating of 2 / 10 to NYXH.

Can you provide the valuation status for NYXOAH SA?

ChartMill assigns a valuation rating of 0 / 10 to NYXOAH SA (NYXH). This can be considered as Overvalued.

Can you provide the profitability details for NYXOAH SA?

NYXOAH SA (NYXH) has a profitability rating of 1 / 10.

What is the financial health of NYXOAH SA (NYXH) stock?

The financial health rating of NYXOAH SA (NYXH) is 2 / 10.

Can you provide the expected EPS growth for NYXH stock?

The Earnings per Share (EPS) of NYXOAH SA (NYXH) is expected to decline by -22.33% in the next year.

NYXOAH SA (NYXH) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

NYXOAH SA / NYXH FAQ

What is the fundamental rating for NYXH stock?

Can you provide the valuation status for NYXOAH SA?

Can you provide the profitability details for NYXOAH SA?

What is the financial health of NYXOAH SA (NYXH) stock?

Can you provide the expected EPS growth for NYXH stock?